Low- and High-Volume Disease in Metastatic Hormone-Sensitive Prostate Cancer: From CHAARTED to PSMA PET—An International Multicenter Retrospective Study

¹Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California;
²Department of Nuclear Medicine, LMU Munich, Munich, Germany;
³Bavarian Cancer Research Center (BZKF), partner site Munich, Munich, Germany;
⁴Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California;
⁵Department of Nuclear Medicine, University Hospital Essen, Essen, Germany;
⁶German Cancer Consortium–University Hospital Essen, Essen, Germany;
⁷Department of Medicine Statistics Core, David Geffen School of Medicine, UCLA, Los Angeles, California;
⁸Department of Nuclear Medicine, University of Pretoria, Pretoria, South Africa;
⁹Department of Radiological Sciences, UCLA, Los Angeles, California;
¹⁰Departments of Medicine and Urology, David Geffen School of Medicine, UCLA, Los Angeles, California;
¹¹Department of Medicine, VA Greater Los Angeles, Los Angeles, California; and
¹²Department of Radiation Oncology, David Geffen School of Medicine, UCLA, Los Angeles, California